The effect of methylprednisolone on the neuromuscular blockade reversal effect of sugammadex

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0002239

Enrollment

Registered

2017-02-22

Start date

2017-01-10

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : At present, the decision to administer methyprednisolone is done by a neurosurgeon considering the size of the tumor and the possiblitiy of adrenal crisis. Therefore, patients will be divided i

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing transsphenodial approach surgery for pituitary tumor American Society of Anesthesiologists (ASA) physical status classification system of I-II Aged 20-60 years

Exclusion criteria

Exclusion criteria: Difficult intuvbation was anticipated If patients had a neuromuscular disorder that could impair neuromuscular block Significant renal or hepatic dysfunction A (family) history of malignant hyperthermia Allergy to narcotics, neuromuscular blocking agents, or other medication used during general anesthesia Receiving medications expected to interfere with the neuromuscular blocking agents

Design outcomes

Primary

Measure	Time frame
The time from the start of sugammadex administration until recovery ot the TOF ratio to 0.9	—

Secondary

Measure	Time frame
Oxygen saturation;Respiratory rate;Blood pressure	—

Countries

Korea, Republic of

Contacts

Public ContactDuk-Hee Chun

Bundang CHA General Hospital

leah1013@chamc.co.kr+82-31-780-5643

Outcome results